



PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(MBHB Case No. 02-090-Z)**

In the Application of:

Bakthavatchalam et al.

Serial No: 10/799,286

Filed: March 12, 2004

For: Capsaicin Receptor Ligands

Group Art Unit: TBD

Examiner: TBD

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to the duty of disclosure provided by 35 C.F.R. § 1.56 and §§ 1.97-98, the applicants wish to make the following references of record in the above-identified application. Copies of the references are enclosed. Copies are also listed in the PTO-1449 form enclosed herewith. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing from the present application.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims, however no such admission is intended. 37 C.F.R. 1.97 (h). The references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is indented as to the relative importance of any portion of the

references. This Statement is not a representation that the cited references have effective dates early enough to be “prior art” within the meaning of 35 U.S.C. sections 102 or 103.

CITED REFERENCES

U.S. Patents

1. U.S. Patent No. 4,424,205 (LaHann et al.)
2. U.S. Patent No. 4,681,897 (Brand)
3. U.S. Patent No. 4,812,446 (Brand)
4. U.S. Patent No. 5,021,450 (Blumberg)
5. U.S. Patent No. 5,290,816 (Blumberg)
6. U.S. Patent No. 5,840,720 (Chen)
7. U.S. Patent No. 5,962,532 (Campbell et al.)
8. U.S. Patent No. 6,248,788 (Robbins et al.)
9. U.S. Patent No. 6,437,147 (Andersen et al.)
10. U.S. Patent No. 6,476,076 (Lee et al.)

U.S. Patent Application Publication

11. U.S. Patent Application Publication 2003/0133951 (Coe et al.)

Foreign Documents

12. WO 99/00115 (Benham et al.)
13. WO 01/85158 (Hogestatt et al.)
14. WO 02/16317 (Suh et al.)
15. WO 02/16318 (Suh et al.)
16. WO 02/16319 (Suh et al.)

17. WO 02/072536 (Thompson et al.)

18. WO 02/076946 (Culshaw et al.)

19. WO 02/090326 (Rami et al.)

Other Documents

20. Bevan et al., *Br. J. Pharmacol.* 107:544-552 (1992)

21. Caterina et al., *Science* 288:306-313 (2000)

22. Dickenson et al., *Br. J. Pharmacol* 104:1045-1049 (1991)

23. Kwak et al., *Neuroscience* 86(2):619-626 (1998)

24. Liu et al., *Neuroscience Letters* 228:29-32 (1997)

25. Ohkubo et al., *J. Dent. Res.* 76(4):848-851 (1997)

26. Santos et al., *Neuroscience Letters* 235:73-76 (1997)

27. Szallasi, *Drugs and Aging* 18:561-573 (2001)

28. Szallasi et al., *Pharmacological Reviews* 51(2):159-211 (1999)

29. Urban et al., *Pain* 89:65-74 (2000)


30. Wu et al., *Gen Pharmac.* 27:151-158 (1996)

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff LLP


Date:

6/3/04

By:



Steven J. Sarussi
Registration No. 32,784

FORM PTO-1449 (Rev. 2-32)	U. S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-090-Z	Serial No. 10/799,286
 INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Bakthavatchalam et al.	
		Filing Date: March 12, 2004	Group:

U. S. PATENT DOCUMENTS

No.	Examiner Initials	Date	Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
1.			4,424,205	3/18/82	LaHann et al.	424	72	01/03/84
2.			4,681,897	12/24/84	Brand	514	557	07/21/87
3.			4,812,446	07/17/87	Brand	514	165	03/14/89
4.			5,021,450	05/30/89	Blumberg	514	453	06/04/91
5.			5,290,816	06/21/90	Blumberg	514	691	03/01/94
6.			5,840,720	10/23/95	Chen	544	230.5	11/24/98
7.			5,962,532	03/12/98	Campbell et al.	514	627	10/05/99
8.			6,248,788	11/06/96	Robbins et al.	514	627	06/19/01
9.			6,437,147	03/16/01	Andersen et al.	548	304.1	08/20/02
10.			6,476,076	02/21/00	Lee et al.	514	580	11/05/02

U. S. PATENT APPLICATION PUBLICATIONS

No.	Examiner Initials	Date	Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
11.			2003/0133951	01/21/03	Coe et al.	424	239.1	07/17/03

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FOREIGN PATENT DOCUMENTS

No.	Examiner Initial	Date	Document Number	Name	Date	Country	Translation	
							Yes	No
12.			WO 99/00115	Benham et al.	07.01.1999	PCT		
13.			WO 01/85158	Hogestatt et al.	15.11.2001	PCT		
14.			WO 02/16317	Suh et al.	28.02.2002	PCT		
15.			WO 02/16318	Suh et al.	28.02.2002	PCT		
16.			WO 02/16319	Suh et al.	28.02.2002	PCT		
17.			WO 02/072536	Thompson et al.	19.09.2002	PCT		
18.			WO 02/076946	Culshaw et al.	03.10.2002	PCT		
19.			WO 02/090326	Rami et al.	14.11.2002	PCT		

OTHER DOCUMENTS

No.	Ex. Initials	Date	
20.			Bevan et al., "Capsazepine: a competitive antagonist of the sensory neuron excitant capsaicin," <i>Br. J. Pharmacol</i> 107:544-52 (1992)
21.			Caterina et al., "Impaired Nociception and Pain Sensation in Mice Lacking the Capsaicin Receptor," <i>Science</i> 288:306-13 (2000)
22.			Dickenson et al., "Selective antagonism of capsaicin by capsazepine: evidence for a spinal receptor site in capsaicin-induced antinociception," <i>Br. J. Pharmacol</i> 104:1045-1049 (1991)
23.			Kwak et al., "A capsaicin-receptor antagonist, capsazepine, reduces inflammation-induced hyperalgesic responses in the rat: evidence for an endogenous capsaicin-like substance," <i>Neuroscience</i> 86(2):619-626 (1998)
24.			Liu et al., "Capsazepine, a vanilloid receptor antagonist, inhibits nicotinic acetylcholine receptors in rat trigeminal ganglia," <i>Neuroscience Letters</i> 228:29-32 (1997)
25.			Ohkubo et al., "The Selective Capsaicin Antagonist Capsazepine Abolishes the Antinociceptive Action of Eugenol and Guaiacol," <i>J. Dent. Res.</i> 76(4):848-851 (1997)
26.			Santos et al., "Ruthenium red and capsazepine antinociceptive effect in formalin and capsaicin models of pain in mice," <i>Neuroscience Letters</i> 235:73-76 (1997)
27.			Szallasi, "Vanilloid Receptor Ligands," <i>Drugs and Aging</i> 18:561-573 (2001)
28.			Szallasi et al., "Vanilloid (Capsaicin) Receptors and Mechanisms," <i>Pharmacological Reviews</i> 51(2):159-211 (1999)
29.			Urban et al., "In vivo pharmacology of SDZ 249-665, a novel, non-pungent capsaicin analogue," <i>Pain</i> 89:65-74 (2000)
30.			Wu et al., "Multiple Sensory and Functional Effects of Non-Phenolic Aminodimethylene Nonivamide: An Approach to Capsaicin Antagonist," <i>Gen. Pharmac.</i> 27:151-158 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.